Program
Anti-NaPi2b/Exatecan Antibody-drug Conjugate TUB-040
Also written as “TUB-040”, “TUB-040 + Carbo + BEV” and “TUB-040 - Dose escalation”.
Its studies are mostly in Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by 2 companies.
Drug pageAnti-NaPi2b/Exatecan Antibody-drug Conjugate TUB-040: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tubulisits history only | 33 open or running | phase 2since Jul 9, 2026 | Jul 9, 2026 | Mar 2028phase 2 · NCT07736937 |
| Gilead Sciencesits history only | 11 open or running | phase 2since Feb 6, 2024 | Feb 6, 2024 | Dec 2027phase 2 · NCT06303505 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 6, 2024First study: phase 2 study in Ovarian NeoplasmsNew to Gilead SciencesGilead Sciences · NCT06303505 · 334 planned · United States, Belgium, Germany and more
- Jul 9, 2026Tubulis’s first studies: 2 phase 2 studiesNew to TubulisTubulis · NCT07736937, NCT07743541
- Sep 1, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungTubulis · NCT07806773 · 80 planned · United States
Ahead
- Dec 2027Primary completion: phase 2 study in Ovarian NeoplasmsGilead Sciences · NCT06303505
- Mar 2028Primary completion: phase 2 study in Ovarian NeoplasmsTubulis · NCT07736937
- May 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungTubulis · NCT07806773
- Sep 2029Primary completion: phase 2 study in Endometrial NeoplasmsTubulis · NCT07743541
TargetBeta
“An antibody-drug conjugate (ADC) composed of a Fc-silenced, humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), ”NCIt, by rule
Other programs on SLC34A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| LM-2417 | Sino Biopharmaceutical | phase 2 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07806773Carcinoma, Non-Small-Cell Lung · United States | 2 | Not yet recruiting | Tubulis | May 2029 | 80 |
| NCT07743541Endometrial Neoplasms · United States | 2 | Not yet recruiting | Tubulis | Sep 2029 | 100 |
| NCT07736937Ovarian Neoplasms · United States, Belgium, Ukraine | 2 | Recruiting | Tubulis | Mar 2028 | 72 |
| NCT06303505Ovarian Neoplasms · United States, Belgium, Germany and more | 2 | Recruiting | Gilead Sciences | Dec 2027 | 334 |
How it is read
Names in the registry
- “TUB-040”, 2 entries
- “TUB-040 + Carbo + BEV”, 1 entry
- “TUB-040 - Dose escalation”, 1 entry
- “TUB-040 - RP2D”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.